Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model

Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that it is well tolerated by patients and has immunomodulatory activity. In our study, using in vitro and in vivo prostate cancer models, we investigated Aneustat with regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Sifeng, Xue, Hui, Dong, Xin, Lin, Dong, Wu, Rebecca, Nabavi, Noushin, Collins, Colin C., Gleave, Martin E., Gout, Peter W., Wang, Yuzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001442/
https://www.ncbi.nlm.nih.gov/pubmed/29441566
http://dx.doi.org/10.1002/ijc.31310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001442/
https://www.ncbi.nlm.nih.gov/pubmed/29441566
http://dx.doi.org/10.1002/ijc.31310

Ejemplares similares